InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
15 hedge funds and large institutions have $1.06M invested in InVivo Therapeutics Holdings Corp in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
9% less capital invested
Capital invested by funds: $1.17M → $1.06M (-$108K)
12% less funds holding
Funds holding: 17 → 15 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$221K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$44.2K |
| 4 |
Two Sigma Investments
New York
|
+$22.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$288K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$167K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$132K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$93K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$10.3K |
NVIV Hedge Fund Activity: Q3 2018 in Review
15 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2018, worth a combined $1.06M — down 9.2% from $1.17M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NVIV and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $221K. The largest seller was Sabby Management, exiting entirely with an estimated $288K sold.
- 15 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2018, down from 17 in Q2 2018.
- Funds reported $1.06M of InVivo Therapeutics Holdings Corp stock for Q3 2018, down 9.2% quarter-over-quarter.
- 3 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2018 and 5 closed out, a net change of -2 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q3 2018 was Renaissance Technologies, an estimated $221K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q3 2018 was Sabby Management, an estimated $288K sold.
Based on aggregated 13F filings for Q3 2018.